CSI Market
Sign In | Register

Atrium Therapeutics Inc (RNA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RNA Annual Cash Flow →
The quarterly cash flow data below helps track how Atrium Therapeutics Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-36.82
Depreciation & amortization0.49
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation13.11
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Noncash Interest Expense0.84
Operating Lease Right Of Use Asset Amortization Expense-1.03
Increase Decrease In Operating Lease Liability-4.64
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.82
Increase (Decrease) in Accounts Payable-0.89
Increase (Decrease) in Accrued Liabilities4.33
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.97
Other Working Capital5.23
Other Noncash Income (Expense)0.00
Other net0.25
Payments for (Proceeds from) Other Operating Activities-24.56
Discontinued operations0.00
Net Cash flow from Operating Activities-35.07
Investing Activities
Capital Expenditures-2.13
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities, Debt-191.55
Payments for Leasing Costs, Commissions, and Tenant Improvements0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-193.69
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Proceeds from Contributions from Affiliates301.51
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock In Initial Public Offering Gross-
Proceeds From Issuance Of Long Term Debt Excluding Convertible Notes-
Distributions To Members-
Proceeds From Issuance Of Common Stock In Public Offering Gross-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities301.51
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-37.20
Total Cash Flow72.75
4 historic quarters locked

Sign in to unlock the full Atrium Therapeutics Inc cash flow history.

Sign In Create Free Account

About Atrium Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: rna-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-349488

Figures are derived from filed reports and may be restated. Historical data is subject to revision.